Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

RBC Capital downgrades ConvaTec after share price strength

Mon 09 December 2019 07:28 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - RBC Capital Markets downgraded its stance on shares of medical products and technologies company ConvaTec to 'sector perform' from 'outperform' on Monday, cutting the price target to 197p from 210p following recent share price strength.

The bank noted that the stock us up 38% in the past six months and advised investors to take profits after a "strong" third quarter.

RBC said the company's third-quarter results drove outperformance of the shares from a low base, with the group's Q3 organic growth the highest in three years and all divisions showing good growth.

However, it noted that ConvaTec cautioned that the fourth quarter will be tougher.

"Tailwinds in Q3 (easy comps and distributor inventory movements) are not expected to repeat, while management expects that Q4 will see some impact from SKU rationalisation, destocking and ID division lumpiness," it said.

At 1040 GMT, the shares were down 1.2% at 190.05p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More company news from ShareCast